title: Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies.
abstract: The impact of human enterovirus (HEV) and human rhinovirus (HRV) respiratory tract infections in adult patients with hematological malignancies has been infrequently reported. We retrospectively studied 31 patients with an upper or lower respiratory tract infection (URTI/LRTI) by HEV (n = 18) or HRV (n = 15). At onset, a LRTI was present in 6 (33%) and 2 (13%) episodes of HEV and HRV infections, respectively, with or without an URTI. Progression to LRTI (pneumonia) from prior URTI was seen in 1 (6%) and 2 (13%) HEV and HRV infections, respectively. The presence of lymphocytopenia (<0.5 x 10(9)/l) was higher in LRTI by HEV: 4/5 (80%) versus 2/10 (20%) by HRV. Eight of 18 (44%) patients with immunosuppression versus 3/14 (21%) patients with no immunosuppression at the onset of respiratory infection developed a LRTI. Thirteen per cent of patients had associated respiratory infections from bacteria, aspergillus, or CMV. Pulmonary aspergillosis was diagnosed in 20% of HRV infections. Three of 11 patients (27%) with a LRTI died, but pulmonary copathogens were also involved in all cases. In conclusion, HEV and HRV can be associated with LRTI in immunocompromised patients, although their direct impact on mortality is uncertain.
authors.affiliation: Department of Clinical Hematology, Autonomous University, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. rparody@hsp.santpau.es
authors.forename: R
authors.initials: R
authors.lastname: Parody
authors.forename: N
authors.initials: N
authors.lastname: Rabella
authors.forename: R
authors.initials: R
authors.lastname: Martino
authors.forename: M
authors.initials: M
authors.lastname: Otegui
authors.forename: M
authors.initials: M
authors.lastname: del Cuerpo
authors.forename: P
authors.initials: P
authors.lastname: Coll
authors.forename: J
authors.initials: J
authors.lastname: Sierra
mesh_terms: D000328:Adult; D000368:Aged; D001228:Aspergillosis / Q000150:complications / Q000175:diagnosis / Q000401:mortality; D001992:Bronchoalveolar Lavage Fluid / Q000821:virology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000175:diagnosis; D018450:Disease Progression; D004769:Enterovirus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology*; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D016867:Immunocompromised Host; D008168:Lung / Q000382:microbiology; D008172:Lung Diseases, Fungal / Q000150:complications / Q000175:diagnosis / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010850:Picornaviridae Infections / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology*; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology*; D012189:Retrospective Studies; D012229:Rhinovirus / Q000302:isolation & purification*; D012621:Seasons; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome